Marker Therapeutics (NASDAQ:MRKR) Trading 3% Higher – Should You Buy?

Marker Therapeutics, Inc. (NASDAQ:MRKR) shares shot up 3% during mid-day trading on Monday . The company traded as high as $1.39 and last traded at $1.37. Approximately 43,227 shares were traded during mid-day trading, a decline of 25% from the average session volume of 57,638 shares. The stock had previously closed at $1.33.

Analysts Set New Price Targets

A number of analysts have commented on MRKR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a report on Friday, March 27th. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Marker Therapeutics has an average rating of “Hold” and an average target price of $10.00.

Marker Therapeutics Stock Performance

The stock has a market capitalization of $21.84 million, a PE ratio of -2.15 and a beta of 1.44. The stock has a 50-day moving average price of $1.46 and a two-hundred day moving average price of $1.51.

Marker Therapeutics (NASDAQ:MRKR) last released its earnings results on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. The company had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. As a group, equities analysts predict that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently made changes to their positions in MRKR. Virtu Financial LLC purchased a new stake in shares of Marker Therapeutics during the 3rd quarter worth approximately $25,000. Two Sigma Investments LP purchased a new position in shares of Marker Therapeutics in the third quarter valued at $33,000. Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the second quarter valued at $33,000. Boyer Financial Services Inc. bought a new stake in Marker Therapeutics in the fourth quarter worth $57,000. Finally, XTX Topco Ltd increased its position in Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares during the last quarter. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.